18F-FDG PET对接受凡德他尼治疗的晚期甲状腺髓样癌患者的预测价值
本研究纳入18例晚期进展性甲状腺髓样癌患者,在凡德他尼治疗前及治疗3个月后行18F-FDG PET/CT,评估代谢参数对无进展生存期和总生存期的预测价值。治疗前SUVmean大于4.0预测显著更短的无进展生存期(1.9年 vs 5.2年,P=0.04);癌胚抗原倍增时间与无进展生存期(r=0.7)和总生存期(r=0.76,P<0.01)显著相关。
要点
- 治疗前肿瘤代谢低(SUVmean小于4.0)预测更长的无进展生存期。
- 治疗前SUVmean大于4.0者无进展生存期显著更短(1.9年 vs 5.2年,P=0.04)。
- 癌胚抗原倍增时间延长与更长的无进展生存期和总生存期显著相关。
核心结论
- 治疗前18F-FDG PET/CT可为计划接受酪氨酸激酶抑制剂凡德他尼治疗的晚期甲状腺髓样癌患者提供预后信息。
- 治疗前肿瘤代谢低(SUVmean小于4.0)预测更长的无进展生存期。
研究设计与样本
- 纳入18例晚期进展性甲状腺髓样癌患者,在凡德他尼治疗开始前及开始后3个月行基线18F-FDG PET/CT。
- 随访期间每3个月行CT扫描并按RECIST标准分析,评估代谢最活跃病灶的18F-FDG SUVmean/max及临床参数对无进展生存期和总生存期的预测价值。
主要发现
- 中位随访5.2年内,9例患者在TKI开始后中位2.1年出现疾病进展,其余患者疾病持续控制(5例部分缓解,4例疾病稳定)。
- 9例疾病进展患者中8例在TKI开始后中位3.5年死于甲状腺髓样癌。
- 治疗前SUVmean大于4.0预测显著更短的无进展生存期(1.9年 vs 5.2年,P=0.04)。
- 治疗3个月时持续高18F-FDG摄取(SUVmean大于2.8)倾向于预示不良预后,无进展生存期1.9年(vs 3.5年,P=0.3),未达统计学显著。
- 癌胚抗原倍增时间延长与更长的无进展生存期(r=0.7)和总生存期(r=0.76,P<0.01)显著相关。
关键数值与推荐
- 治疗前SUVmean大于4.0预测显著更短的无进展生存期(1.9年 vs 5.2年,P=0.04)。
- 治疗3个月时SUVmean大于2.8倾向于预示不良预后,无进展生存期1.9年(vs 3.5年,P=0.3)。
- 癌胚抗原倍增时间延长与更长的无进展生存期(r=0.7)和总生存期(r=0.76,P<0.01)显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly improved since the introduction of tyrosine kinase inhibitors (TKIs). We aimed to assess the role of metabolic imaging using 18F-FDG PET/CT shortly before and 3 mo after initiation of TKI treatment. Methods: Eighteen patients with advanced and progressive MTC scheduled for vandetanib treatment underwent baseline 18F-FDG PET/CT before and 3 mo after TKI treatment initiation. During follow-up, CT scans were obtained every 3 mo and analyzed according to RECIST. The predictive value for estimating progression-free survival (PFS) and overall survival (OS) was examined by investigating the 18F-FDG SUVmean/max of the metabolically most active lesion, as well as by analyzing clinical parameters (tumor marker doubling times [calcitonin, carcinoembryonic antigen], prior therapies, rearranged-during-transfection mutational status, and disease type). Results: Within a median follow-up of 5.2 y, 9 patients experienced disease progression after a median interval of 2.1 y, whereas the remainder had ongoing disease control (5 with a partial response and 4 with stable disease). Eight of the 9 patients with progressive disease died from MTC after a median of 3.5 y after TKI initiation. A pretherapeutic SUVmean of more than 4.0 predicted a significantly shorter PFS (1.9 y vs. 5.2 y, P = 0.04). Furthermore, sustained high 18F-FDG uptake at 3 mo with a SUVmean of more than 2.8 tended to portend an unfavorable prognosis, with a PFS of 1.9 y (vs. 3.5 y, P = 0.3). Prolonged carcinoembryonic antigen doubling times were significantly correlated with longer PFS (r = 0.7) and OS (r = 0.76, P < 0.01). None of the other clinical parameters had prognostic significance. Conclusion: Pretherapeutic 18F-FDG PET/CT provides prognostic information in patients with advanced MTC scheduled for treatment with the TKI vandetanib. A low tumor metabolism with an SUVmean of less than 4.0 before treatment predicts a longer PFS.
引用
- Werner RA, Schmid JS, Higuchi T, et al. Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib. J Nucl Med. 2017. PMID: 29025983. doi:10.2967/jnumed.117.199778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。